ZIVO
Income statement / Annual
Last year (2023), ZIVO Bioscience, Inc.'s total revenue was $27,650.00,
and the percentage change from the previous year is not available.
In 2023, ZIVO Bioscience, Inc.'s net income was -$7.78 M.
See ZIVO Bioscience, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$27,650.00
|
$0.00
|
$0.00
|
$20,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$16,040.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
$11,610.00 |
$0.00 |
$0.00 |
$20,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit Ratio |
0.42 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$1.38 M
|
$2.24 M
|
$2.12 M
|
$3.75 M
|
$2.31 M
|
$2.81 M
|
$2.38 M
|
$788,971.00
|
$1.03 M
|
$1.97 M
|
General & Administrative
Expenses |
$5.90 M
|
$6.49 M
|
$6.93 M
|
$4.82 M
|
$6.05 M
|
$3.32 M
|
$3.95 M
|
$2.70 M
|
$2.02 M
|
$1.59 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$198,632.00
|
Selling, General &
Administrative Expenses |
$5.90 M
|
$6.49 M
|
$6.93 M
|
$4.82 M
|
$6.05 M
|
$3.32 M
|
$3.95 M
|
$2.70 M
|
$2.02 M
|
$1.79 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$7.27 M |
$8.73 M |
$9.05 M |
$8.58 M |
$8.35 M |
$6.13 M |
$6.33 M |
$3.49 M |
$3.06 M |
$3.76 M |
Cost And Expenses |
$7.29 M |
$8.73 M |
$9.05 M |
$8.58 M |
$8.35 M |
$6.13 M |
$6.33 M |
$3.49 M |
$3.06 M |
$3.76 M |
Interest Income |
$0.00 |
$13,319.00 |
$233,282.00 |
$550,054.00 |
$3.16 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$514,172.00 |
$13,319.00 |
$233,281.00 |
$550,054.00 |
$3.16 M |
$8.10 M |
$1.83 M |
$986,188.00 |
$720,711.00 |
$589,573.00 |
Depreciation &
Amortization |
$439,594.00
|
$4.00
|
-$407,491.00
|
$8.56 M
|
$8.35 M
|
$18,750.00
|
$18,750.00
|
$25,000.00
|
$25,000.00
|
$29,835.00
|
EBITDA |
-$7.26 M
|
-$8.73 M
|
-$9.05 M
|
-$8.56 M
|
-$8.35 M
|
-$6.54 M
|
-$6.53 M
|
-$3.65 M
|
-$3.21 M
|
-$3.90 M
|
EBITDA Ratio |
-262.68 |
0 |
0 |
-427.78 |
0 |
0 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
-262.68
|
0
|
0
|
-427.78
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
-$514,172.00
|
-$13,319.00
|
-$110,761.00
|
-$550,054.00
|
-$3.16 M
|
-$8.50 M
|
-$1.66 M
|
-$1.40 M
|
-$1.83 M
|
$5.20 M
|
Income Before Tax |
-$7.78 M |
-$8.75 M |
-$9.16 M |
-$9.11 M |
-$11.51 M |
-$14.64 M |
-$10.04 M |
-$6.06 M |
-$5.79 M |
$680,811.00 |
Income Before Tax Ratio
|
-281.27
|
0
|
0
|
-455.29
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$167,895.00 |
-$4.00 |
$233,281.00 |
$550,054.00 |
$3.16 M |
$407,487.00 |
$1.66 M |
$1.40 M |
$1.83 M |
-$5.20 M |
Net Income |
-$7.78 M |
-$8.75 M |
-$9.40 M |
-$9.66 M |
-$14.67 M |
-$14.64 M |
-$10.04 M |
-$6.06 M |
-$5.79 M |
$680,811.00 |
Net Income Ratio |
-281.27 |
0 |
0 |
-482.79 |
0 |
0 |
0 |
0 |
0 |
0 |
EPS |
-4.48 |
-5.58 |
-7.4 |
-11.41 |
-25.47 |
-44.84 |
-34.6 |
-21.73 |
-21.22 |
1.79 |
EPS Diluted |
-4.48 |
-5.57 |
-7.39 |
-11.41 |
-25.47 |
-44.84 |
-34.6 |
-21.73 |
-21.22 |
1.79 |
Weighted Average Shares
Out |
$1.74 M
|
$1.57 M
|
$1.27 M
|
$846,212.00
|
$575,826.00
|
$326,414.00
|
$290,090.00
|
$278,842.00
|
$272,804.00
|
$379,594.00
|
Weighted Average Shares
Out Diluted |
$1.74 M
|
$1.57 M
|
$1.27 M
|
$846,212.00
|
$575,826.00
|
$326,414.00
|
$290,090.00
|
$278,842.00
|
$272,804.00
|
$379,594.00
|
Link |
|
|
|
|
|
|
|
|
|
|